These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 960872)

  • 1. [Nephrotic syndrome after treatment with penicillamine in Wilson's disease].
    Hampel R; Meng W; Kallwellis G
    Z Gesamte Inn Med; 1976 Jul; 31(13):507-11. PubMed ID: 960872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system].
    Hayek HW; Schnack H; Widhalm S
    Wien Klin Wochenschr; 1973 Feb; 85(8):122-5. PubMed ID: 4632215
    [No Abstract]   [Full Text] [Related]  

  • 4. [Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson's disease].
    Farallo M; Amoruso C; Frattini C; Ardissino G; Nebbia G
    Pediatr Med Chir; 2012; 34(5):234-6. PubMed ID: 23342748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ophthalmoscopic changes in a patient with Wilson's disease during long-term penicillamine therapy.
    Dingle J; Havener WH
    Ann Ophthalmol; 1978 Sep; 10(9):1227-30. PubMed ID: 736410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Penicillamine and other therapeutic methods in the treatment of Wilson's disease].
    Czlonkowska A; Czlonkowski A
    Neurol Neurochir Pol; 1975; 9(3):401-6. PubMed ID: 1097955
    [No Abstract]   [Full Text] [Related]  

  • 7. [Wilson's disease--critical deterioration under high-dose parenteral penicillamine therapy].
    Hilz MJ; Druschky KF; Bauer J; Neundörfer B; Schuierer G
    Dtsch Med Wochenschr; 1990 Jan; 115(3):93-7. PubMed ID: 2298126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotic syndrome in the course of treatment of Wilson's disease with DL-penicillamine.
    Karp M; Lurie M; Yonis Z
    Arch Dis Child; 1966 Dec; 41(220):684-7. PubMed ID: 5927925
    [No Abstract]   [Full Text] [Related]  

  • 9. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the therapeutic combination of S-adenosylmethionine with D-penicillamine in Wilson's disease].
    Gasbarrini G; Miglio F; Corazza GR; Stefanini GF
    Minerva Med; 1975 May; 66(33):1600-4. PubMed ID: 1143693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2 cases of verruciform perforating elastoma after prolonged administration of D-penicillamine in Wilson's disease].
    Sfar Z; Lakhoua H; Hafsia M; Amor RB; Mahfoudh H; Hamza B; Abdallah CB
    Tunis Med; 1977; 55(3):167-8. PubMed ID: 919044
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.
    Walshe JM
    Lancet; 1969 Dec; 2(7635):1401-2. PubMed ID: 4188283
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease.
    Marecek Z; Heyrovský A; Volek V
    Acta Hepatogastroenterol (Stuttg); 1975 Oct; 22(5):292-6. PubMed ID: 1199668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Penicillamine-induced dermolytic dermatosis in a patient with Wilson's disease (author's transl)].
    Bardach H; Gebhart W
    Dermatologica; 1981; 162(6):473-83. PubMed ID: 7274508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
    Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
    Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatolenticular degeneration, Wilson's disease. A characteristics case with remission under penicillamine therapy].
    Hansen J; Andersen OS
    Ugeskr Laeger; 1969 Jul; 131(31):1306-9. PubMed ID: 5824791
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunologic studies with the lymphocyte transformation test on the side effects of D-penicillamine therapy in Wilson's disease].
    Storch W; Berger H
    Z Gesamte Inn Med; 1980 Jul; 35(13):567-70. PubMed ID: 7445606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [D-penicillamine-induced IgA deficiency in the therapy of Wilson's disease].
    Ibel H; Feist D; Endres W; Belohradsky BH
    Klin Padiatr; 1990; 202(6):427-9. PubMed ID: 2266710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.